Aficamten

CAS No.	2364554-48-1
MDL No.	N/A
MF	C₁₈H₁₉N₅O₂
MW	337.40
InChI Key	IOVAZWDIRCRMTM-OAHLLOKOSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	2364554-48-1
Product Name	Aficamten

Associated Conditions

hypertrophic cardiomyopathy·cardiomyopathy

* The information provided here is compiled from public sources and is for reference only.

Aficamten

CAS No.	2364554-48-1
MDL No.	N/A
MF	C₁₈H₁₉N₅O₂
MW	337.40
InChI Key	IOVAZWDIRCRMTM-OAHLLOKOSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	2364554-48-1
Product Name	Aficamten

Associated Conditions

hypertrophic cardiomyopathy·cardiomyopathy

* The information provided here is compiled from public sources and is for reference only.

Aficamten

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Aficamten

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Documentation

Aficamten

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

Obstructive hypertrophic cardiomyopathy: a review of new therapies.

Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.

Emerging Medical Treatment for Hypertrophic Cardiomyopathy.

Aficamten

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

Obstructive hypertrophic cardiomyopathy: a review of new therapies.

Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.

Emerging Medical Treatment for Hypertrophic Cardiomyopathy.

Documentation